Charles Schwab Investment Management Inc. Acquires 18,168 Shares of STAAR Surgical (NASDAQ:STAA)

Charles Schwab Investment Management Inc. lifted its holdings in STAAR Surgical (NASDAQ:STAA) by 4.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 444,290 shares of the medical instruments supplier’s stock after acquiring an additional 18,168 shares during the period. Charles Schwab Investment Management Inc.’s holdings in STAAR Surgical were worth $10,792,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in STAA. Geode Capital Management LLC lifted its stake in STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after purchasing an additional 31,212 shares during the last quarter. HighTower Advisors LLC bought a new stake in STAAR Surgical in the third quarter worth about $336,000. Polar Asset Management Partners Inc. lifted its stake in STAAR Surgical by 44.3% in the third quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock worth $6,271,000 after purchasing an additional 51,800 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after purchasing an additional 172,779 shares during the last quarter. Finally, Defender Capital LLC. lifted its stake in STAAR Surgical by 3.5% in the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock worth $17,041,000 after purchasing an additional 23,950 shares during the last quarter. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Down 1.1 %

Shares of STAA stock opened at $17.72 on Friday. The firm has a market cap of $874.04 million, a price-to-earnings ratio of -43.22 and a beta of 0.66. The company’s 50 day moving average is $19.87 and its 200 day moving average is $25.66. STAAR Surgical has a 52-week low of $13.50 and a 52-week high of $52.68.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were bought at an average cost of $21.50 per share, with a total value of $176,751.50. Following the completion of the acquisition, the insider now directly owns 10,878,007 shares in the company, valued at $233,877,150.50. This represents a 0.08 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired a total of 1,036,187 shares of company stock valued at $17,239,548 over the last ninety days. 1.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on STAA shares. Canaccord Genuity Group decreased their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Mizuho downgraded shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Stifel Nicolaus decreased their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Finally, StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, STAAR Surgical currently has a consensus rating of “Hold” and a consensus target price of $25.29.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.